Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771713 | 0.89 | LMNA (0.40) | AHRCFTRBRD4MEN1KMT2A | |
| SCHEMBL6772243 | 0.88 | RXFP1 (0.44) | AHRMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL6777504 | 0.88 | TYK2 (0.43) | KMT2ABUB1ALDH1A1ROCK2ROCK1 | |
| SCHEMBL6772359 | 0.86 | POLB (0.49) | AHRMEN1KMT2AHPGDTDP1 | |
| SCHEMBL6770247 | 0.86 | ALDH1A1 (0.46) | MEN1KMT2AHPGDTDP1ALDH1A1 | |
| SCHEMBL6773137 | 0.85 | CREBBP (0.47) | CREBBPMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5735789 | 0.85 | NHERF1 (0.46) | AHRCFTRHPGDALDH1A1ROCK2 | |
| SCHEMBL6773412 | 0.84 | BRD4 (0.52) | CREBBPBRD4MEN1KMT2AHPGD | |
| SCHEMBL5735503 | 0.83 | CFTR (0.39) | AHRCFTRCREBBPBRD4KMT2A | |
| SCHEMBL6778657 | 0.83 | SNCA (0.44) | AHRCFTRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | claimed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | claimed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | claimed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | claimed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | claimed |
| US-20040258940-A1 | Recording sheet and method for recording image using the same | FUJI XEROX CO., LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | disclosed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | disclosed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | GABRA1, GABRA4, GABRA2 | AHR 387/4885CFTR 3339/4885CREBBP 1261/4885 |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | CNR1, HTR1A, GABRA6 | AHR 150/4885CFTR 3595/4885CREBBP 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.